[1]苏 虹a,李仕林b,王昌育a,等.成纤维细胞生长因子23 基因多态性与慢性心力衰竭患者预后的相关性研究[J].现代检验医学杂志,2020,35(01):35-39.[doi:10.3969/j.issn.1671-7414.2020.01.010]
　SU Honga,LI Shi-linb,WANG Chang-yua,et al.Association of Fibroblast Growth Factors 23 Gene Polymorphism and Prognosis in Patients with Chronic Heart Failure[J].Journal of Modern Laboratory Medicine,2020,35(01):35-39.[doi:10.3969/j.issn.1671-7414.2020.01.010]
点击复制

成纤维细胞生长因子23 基因多态性与慢性心力衰竭患者预后的相关性研究()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第35卷
期数:
2020年01期
页码:
35-39
栏目:
论　　著
出版日期:
2020-02-29

文章信息/Info

Title:
Association of Fibroblast Growth Factors 23 Gene Polymorphism and Prognosis in Patients with Chronic Heart Failure
文章编号:
1671-7414(2020)01-035-05
作者:
苏 虹1a; 李仕林1b; 王昌育1a; 张 环1a; 张维娟1a; 侯 红1a; 王 东1a; 严定一1a; 闫生玲2
(1.西安市第三医院a.心血管内科; b.神经内科,西安 710018; 2. 延安市人民医院心血管内科,陕西延安 716000)
Author(s):
SU Hong1a;  LI Shi-lin1b;  WANG Chang-yu1a;  ZHANG Huan1a;  ZHANG Wei-juan1a;  HOU Hong1a;  WANG Dong1a;  YAN Ding-yi1a; YAN Sheng-ling
(1a. Department of Cardiology Medicine; 1b. Department of Neurology, Xi'an Third Hospital,Xi'an 710018,China; 2. Department of Cardiology Medicine, Yan'an People's Hospital, Shaanxi Yan'an 716000, China)
关键词:
成纤维细胞生长因子23;  慢性心力衰竭;  单核苷酸多态性;  预后
分类号:
R541.6; Q786
DOI:
10.3969/j.issn.1671-7414.2020.01.010
文献标志码:
A
摘要:
目的 探讨陕西地区汉族人群中成纤维细胞生长因子23(fibroblast growth factors 23,FGF-23)基因多态性与慢性心力衰竭(chronic heart failure,CHF)患者预后的关系。方法 于2014年1月～2017年6月在西安市第三医院和西安市第二医院心血管内科收集的349例CHF患者作为受试对象,根据随访2.5年内患者是否发生心血管事件分为预后不良组与预后良好组,采用聚合酶链反应-直接测序法检测FGF-23基因rs7955866,rs13312756和rs3812822位点的多态性。结果 预后不良组与预后良好组比较,两组患者年龄(t=2.621)、脑钠肽水平(t=3.913)、NYHA分级(χ2=6.296)、左室舒张末期内径(t=2.805)、右室舒张末期内径(t=2.73)、左室射血分数超声测值(t=2.275)等参数比较,差异具有统计学意义(均P<0.05)。rs7955866位点基因多态性在等位基因模型和显性基因模型下与CHF患者发生心血管事件相关(OR=1.911,95%CI 1.210～3.018,P=0.005; OR=2.149,95%CI 1.275～3.632,P=0.004); rs3812822位点基因多态性在等位基因模型和显性基因模型下与CHF患者发生心血管事件相关(OR=1.763,95%CI 1.153～1.696,P=0.008; OR=2.046,95%CI 1.237～3.384,P=0.005); rs13312756位点基因多态性在各基因模型下均与CHF患者发生心血管事件无关(均P>0.05)。Logistics多因素回归分析结果显示携带rs7955866 A等位基因、rs3812822 C等位基因均是CHF患者预后不良的危险因素(OR=1.368,95%CI 1.107～3.684,P=0.007; OR=1.274,95%CI 1.086～3.872,P=0.011)。结论 陕西地区汉族人群中,FGF-23基因多态性与CHF患者预后相关。
Abstract:
Objective To investigate the genetic association between fibroblast growth factors 23(FGF-23)gene polymorphism and prognosis in patients with chronic heart failure(CHF)in the Han descent population of Shaanxi province. Methods 349 CHF patients were enrolled in the Department of Cardiology Medicine, Xi'an Third Hospital and Xi'an Second Hospital from January 2014 to June 2017. According to whether with cardiovascular events occurred during the follow-up period of 2.5 year, they were divided into great prognosis group and poor prognosis group. Genotype was determined by polymerase chain reaction - direct sequencing for the polymorphism of the FGF-23 gene rs7955866, rs13312756 and rs3812822. Results There were significant differences in age(t=2.621), brain natriuretic peptide level(t=3.913), NYHA classification(χ2=6.296), left ventricular end-diastolic diameter(t=2.805), right ventricular end-diastolic diameter(t=2.730), left ventricular ejection fraction(t=2.275)and other parameters between the poor prognosis group and the good prognosis group(all P< 0.05). Significant association could be found in allele model and dominant gene model between rs7955866 gene polymorphism and cardiovascular events(OR=1.911,95%CI 1.210～3.018,P=0.005; OR=2.149,95%CI 1.275～3.632,P=0.004), and in allele model and dominant gene model between rs3812822 gene polymorphism and cardiovascular events(OR=1.763,95%CI 1.153～1.696,P=0.008; OR=2.046,95%CI 1.237～3.384,P=0.005). There was no significant association between rs13312756 gene polymorphism and cardiovascular events under any gene model(all P>0.05). Multivariate Logistic regression analysis showed that rs7955866 A allele and rs3812822 C allele were predictive factors of cardiovascular events for CHF patients(OR=1.368,95%CI 1.107～3.684,P=0.007; OR=1.274,95%CI 1.086～3.872,P=0.011). Conclusion FGF-23 gene polymorphism was associated with prognosis of CHF patients in Han population in Shaanxi Province.

参考文献/References:

[1] APPEL L J, FELDMAN H I, GO A S, et al. Inflammation and elevated levels of fibroblast growth factor 23 are independent risk factors for death in chronic kidney disease[J]. Kidney Int, 2016, 91(3):711-719.
[2] MASSON S, AGABITI N, VAGO T, et al. The fibroblast growth factor-23 and vitamin D emerge as nontraditional risk factors and may affect cardiovascular risk[J]. J Intern Med, 2015, 277(3):318-330.
[3] GRABNER A, AMARAL A P, SCHRAMM K, et al. Activation of cardiac fibroblast growth factor receptor 4 causes left ventricular hypertrophy[J]. Cell Metabolism, 2015, 22(6):1020-1032.
[4] REINDL M, REINSTADLER S J, FEISTRITZER H J, et al. Fibroblast growth factor 23 as novel biomarker for early risk stratification after ST-elevation myocardial infarction[J]. Heart, 2017, 103(11):856-862.
[5] GAN Lu, ZHOU Qiaoling. Correlations of FGF23 and Klotho with cardiovascular injury in chronic kidney disease patients[J]. Journal of Central South University(Medical science), 2017, 42(9):1058-1065.
[6] BRANDENBURG V M, KLEBER M E, VERVLOET M G, et al. Fibroblast growth factor 23(FGF23)and mortality: The ludwigshafen risk and cardiovascular health study[J]. Atherosclerosis, 2014, 237(1):53-59.
[7] ISHII T, GEMMA A, KIDA K. Senescence is involved in the pathogenesis of chronic obstructive pulmonary disease through effects on telomeres and the anti-aging molecule fibroblast growth factor 23.[J]. Geriatr Gerontol Int, 2015, 15(7):827-833.
[8] KIM H J, KIM K, LEE J, et al. Single nucleotide polymorphisms in fibroblast growth factor 23 gene, FGF23, are associated with prostate cancer risk[J]. BJU Int, 2014, 114(2):303-310.
[9] MENG Q H, XU E, HILDEBRANDT M A, et al. Genetic variants in the fibroblast growth factor pathway as potential markers of ovarian cancer risk, therapeutic response, and clinical outcome.[J]. Clin Chem, 2014, 60(1):222-232.
[10] 崔贞, 刘 文. 慢性心力衰竭患者呋塞米治疗对血清NT-proBNP水平的影响[J]. 现代检验医学杂志, 2019, 34(3):144-147. CUI Zhen, LIU Wen. Effects of furosemide in patientswith chronic heart failure on serum NT-proBNP [J]. Journal of Modern Laboratory Medicine, 2019, 34(3):144-147.
[11] 唐红秀, 王 璐, 万 楠, 等. 慢性心力衰竭患者外周血RDW与HDL-C水平的相关性分析[J]. 现代检验医学杂志, 2018, 33(6):88-90,94. TANG Hongxiu, WANG Lu, WAN Nan et al. Relationship between high-density lipoprotein cholesterol and the red cell distribution width in patients with chronic heart failure[J]. Journal of Modern Laboratory Medicine, 2018, 33(6):88-90,94.
[12] 中华医学会心血管病学分会,中华心血管病杂志编辑委员会. 中国心力衰竭诊断和治疗指南2014[J]. 中华心血管病杂志, 2014, 42(2):98-122. Society of Cardology of Chinese Medical Association, Editorial Board of Chinese Journal of Cardiology. Guidelines for diagnosis and treatment of heart failure in China, 2014 [J]. Chinese Journal of Cardiology, 2014,42(2):98-122.
[13] IMAZU M, TAKAHAMA H, AMAKI M, et al. Use of serum fibroblast growth factor 23 vs. plasma B-type natriuretic peptide levels in assessing the pathophysiology of patients with heart failure[J]. Hypertens Res, 2017, 40(2):181-188.
[14] VON JEINSEN B, SOPOVA K, PALAPIES L, et al. Bone marrow and plasma FGF-23 in heart failure patients: novel insights into the heart–bone axis[J]. ESC Heart Failure, 2019, 6(3): 536–544.
[15] BERGMARK B A, UDELL J A, MORROW D A, et al. Association of fibroblast growth factor 23 with recurrent cardiovascular events in patients after an acute coronary syndrome[J]. JAMA Cardiology, 2018, 3(6): 473-480.
[16] PEKKINEN M, LAINE C M, MKITIE R, et al. FGF23 gene variation and its association with phosphate homeostasis and bone mineral density in Finnish children and adolescents[J]. Bone, 2015, 71:124-130.
[17] 蔡鹏, 仲伟天, 彭岩,等. 重庆地区汉族人群FGF23基因多态性与冠心病的相关性分析[J]. 第三军医大学学报, 2016, 38(6):657-662.CAI Peng, Zhong Weitian, PENG Yan, et al. Correlation of FGF23 genetic polymorphism and coronary heart disease in Chongqing Han population [J]. Journal of the Third Military Medical University, 2016, 38(6):657-662.

相似文献/References:

[1]滑 艳,王海疆.尿液NT-proBNP水平在慢性心力衰竭诊断中的意义[J].现代检验医学杂志,2015,30(02):134.[doi:10.3969/j.issn.1671-7414.2015.02.042]
　HUA Yan,WANG Hai-jiang.Significance of Urinary NT-proBNP Levels for Diagnosis of Chronic Heart Failure[J].Journal of Modern Laboratory Medicine,2015,30(01):134.[doi:10.3969/j.issn.1671-7414.2015.02.042]
[2]李婷婷,陈 凤,刘 然.阿尔茨海默病患者血清FGF23 和ZAG 水平表达与认知功能的相关性分析[J].现代检验医学杂志,2023,38(06):166.[doi:10.3969/j.issn.1671-7414.2023.06.030]
　LI Tingting,CHEN Feng,LIU Ran.Correlation Analysis between Serum FGF23 and ZAG Levels and Cognitive Function in Patients with Alzheimer’s Disease[J].Journal of Modern Laboratory Medicine,2023,38(01):166.[doi:10.3969/j.issn.1671-7414.2023.06.030]

备注/Memo

备注/Memo:
作者简介:苏虹(1984-),女,硕士,主治医师,研究方向:心力衰竭、冠心病,E-mail:xian su hong@163.com。 通讯作者:李仕林,男,研究生,主治医师,研究方向:脑血管疾病,E-mail:lihuashiling@126.com。收稿日期:2019-08-10 修稿日期:2019-08-28
更新日期/Last Update: 2020-03-30